Morgan Stanley heads into the final stretch of August with the short story essentially closed — the live question is whether the stock at $217.55 can close a meaningful gap to analyst targets that mostly cluster between $240 and $262.
Short interest has stabilised at the floor it found last week. Positions held at 12.6 million shares through the week — just 0.79% of the free float — essentially unchanged since the dramatic collapse from 17.1 million on August 7. That 27% drop month-on-month was the story of the prior note; this week, the covering has simply stopped rather than reversed. The borrow market corroborates: availability is effectively unlimited, with roughly 699 million shares available against 12.6 million short. Cost to borrow did tick up sharply on the week — doubling to 0.46% — but remains close to its lowest levels of the past 30 days in absolute terms and well below any level that would signal friction. The ORTEX short score nudged up fractionally to 29.65, after falling off a cliff on August 10. Bears have left the building; the marginal move in borrow cost is noise, not a rebuild.
Options tell a similarly settled story. The put/call ratio is 1.46, almost exactly in line with its 20-day average of 1.45 — a z-score of just 0.39, barely above the mean. The ratio has been remarkably flat since early July, oscillating between 1.41 and 1.50 with no directional move. At 1.46, it sits comfortably below the 52-week high of 1.62 and above the low of 1.18. There is no defensive skew building ahead of the October 14 earnings date. Positioning looks neutral rather than hedged.
The Street angle is where the tension lives. Analyst targets raised in July following Q2 results clustered around $240–$262, with UBS the most recent mover on August 3, lifting to $260 while maintaining its Buy. JP Morgan's Neutral carries a $195 target — the clear outlier on the downside, sitting 10% below the current price. The consensus is technically a Hold (12 Hold ratings, 1 Underperform, and several Outperforms in the mix), but the direction of travel from July's target revisions was uniformly upward. Bulls point to M&A pipeline recovery, digital wealth expansion, and a demonstrated ability to beat estimates — the EPS surprise factor ranks in the 82nd percentile. Bears flag the company's exposure to equity capital markets volatility and the risk that trading revenues soften if macro conditions deteriorate. With the stock at $217.55, the mean target implies roughly 15–20% upside depending on which targets you average — a gap wide enough to matter, but one that has existed for most of the year.
The institutional register is worth a glance for one reason. Mitsubishi UFJ Financial Group, Morgan Stanley's largest single shareholder at just under 24% of shares outstanding, trimmed 414,000 shares in late July — a modest reduction on a position of nearly 377 million shares. The CFO, Sharon Yeshaya, also sold just over 15,500 shares at around $222 on July 16, immediately after earnings. Neither move is alarming in scale, but both came near recent price highs. The more constructive institutional signal comes from Capital Research, FMR, Norges Bank, T. Rowe Price, and JP Morgan Asset Management, each of which added meaningfully to positions in the June–July reporting period.
The next scheduled earnings date is October 14. The most recent print on July 15 saw the stock fall 4.1% on the day and extend losses to roughly 4% by the end of the week — the clean narrative being that the results were strong enough to lift targets but not strong enough to lift the stock, which had already re-rated heading into the release. The setup into October will therefore be worth watching: whether the $217–$220 range proves sticky ahead of results, and whether the gap to analyst targets narrows through price appreciation or through further target revisions lower from the holdouts.
See the live data behind this article on ORTEX.
Open MS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
